
NASDAQHealthcareMedical - Healthcare Information Services
ข้อมูลล่าสุด
US$69.28
−US$1.07 · -1.52%
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
ณ ราคาปิด
US$69.28
−US$1.07 · -1.52%
หลังปิดตลาด
US$69.24
−US$0.04 · -0.06%
8 ต.ค. 19:59 ET
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
ช่วงราคารายวัน
ปัจจุบัน US$69.28
ช่วง 52 สัปดาห์
ปัจจุบัน US$69.28
เวลาในวันใช้เขตเวลาET ข้อมูลตลาดอาจล่าช้า
คะแนน GoAI
ถือ
มูลค่า
72
ต่ำกว่ามูลค่า
ความเชื่อมั่น
47
ผสม
ความเสี่ยง
82
ความเสี่ยงสูงมาก
โมเมนตัม
48
เป็นกลาง
งานวิจัย GoAI ฉบับเต็ม
ดูข้อมูลสนับสนุน ปัจจัยหนุน และความเสี่ยงในเชิงลึก
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
ช่วงราคารายวัน
ปัจจุบัน US$69.28
ช่วง 52 สัปดาห์
ปัจจุบัน US$69.28
อัตรากำไรที่รายงานในช่วงเวลาที่มีอยู่
รายได้
รายได้จากการดำเนินงาน
รายได้สุทธิ
| รายการ (USD) | ปีงบประมาณ 2025 | ปีงบประมาณ 2024 | ปีงบประมาณ 2023 | ปีงบประมาณ 2022 | ปีงบประมาณ 2021 |
|---|---|---|---|---|---|
| รายได้ | 1.27B USD | 693.4M USD | 531.82M USD | 320.67M USD | 257.85M USD |
| ต้นทุนสินค้าขาย | 473.89M USD | 312.29M USD | 245.65M USD | 190.48M USD | 174.21M USD |
| กำไรขั้นต้น | 797.9M USD | 381.11M USD | 286.18M USD | 130.19M USD | 83.64M USD |
| การวิจัยและพัฒนา | 319.03M USD | 316.84M USD | 185.5M USD | 162.25M USD | 128.35M USD |
| การขาย ทั่วไป และธุรการ | 715.43M USD | 755.35M USD | 296.76M USD | 233.38M USD | 199M USD |
| ค่าใช้จ่ายในการดำเนินงาน | 1.05B USD | 1.07B USD | 482.26M USD | 395.63M USD | 327.36M USD |
| รายได้ดอกเบี้ย | 12.63M USD | 11.08M USD | 7.6M USD | 3.03M USD | 623K USD |
| ดอกเบี้ยจ่าย | 70.27M USD | 53.65M USD | 46.87M USD | 21.89M USD | 15.18M USD |
| ค่าเสื่อมราคาและค่าตัดจำหน่าย | 102.32M USD | 37.25M USD | 33.33M USD | 30.41M USD | 23.88M USD |
| รายได้จากการดำเนินงาน | −252.87M USD | −691.08M USD | −196.08M USD | −265.44M USD | −243.71M USD |
| รายได้สุทธิ | −245.03M USD | −705.81M USD | −214.12M USD | −289.81M USD | −259.19M USD |
ข้อเท็จจริงของบริษัทได้รับการปรับปรุง 9 ต.ค. 2569.
ผลประกอบการล่าสุดที่ประกาศ
ผลประกอบการล่าสุดที่ประกาศ
ประมาณการของนักวิเคราะห์ภายนอกอาจเปลี่ยนแปลงและไม่ใช่คำแนะนำของ GoAI
เป้าหมายเฉลี่ย
US$72.60
โอกาสปรับขึ้น 4.79%กองทุนซื้อขายแลกเปลี่ยนที่รายงานความเสี่ยงต่อหุ้นนี้
ARK Innovation ETFARKK565.35M5.10%5.56B USD0.75%US$87.60-0.79%
Vanguard Morningstar Total Stock Market ETFVTI227.53M0.01%2.3T USD0.03%US$379.56-0.39%
ARK Genomic Revolution ETFARKG175.75M8.33%1.56B USD0.75%US$49.29-1.70%
Vanguard Morningstar Small-Cap ETFVB164.58M0.09%185.3B USD0.03%US$287.63+0.23%
Vanguard Morningstar Small-Cap Growth ETFVBK94.47M0.21%44.7B USD0.05%US$340.59-0.48%
Vanguard Extended Market ETFVXF75.5M0.08%95.4B USD0.05%US$233.13-0.15%
iShares Biotechnology ETFIBB57.3M0.55%10.41B USD0.44%US$200.48-1.41%
JPMorgan U.S. Tech Leaders ETFJTEK56.01M1.15%4.8B USD0.65%US$106-1.32%
ARK Innovation ETFARKK
Vanguard Morningstar Total Stock Market ETFVTI
ARK Genomic Revolution ETFARKG
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Biotechnology ETFIBB
JPMorgan U.S. Tech Leaders ETFJTEKเนื้อหาที่สร้างโดย AI และข้อมูลตลาดที่ล่าช้ามีไว้เพื่อให้ข้อมูลและการศึกษาเท่านั้น ไม่ใช่คำแนะนำการลงทุน